Illumina delivered a robust start to 2026 in Q1, outperforming guidance across revenue, margins, and earnings. Reported revenue of $1.091B rose 4.8% YoY (1.2% organic), led by strong instrument sales and clinical consumables growth, with Rest of World (RoW) organic growth at 3.5% and NovaSeq X placements exceeding targets (80 units in Q1, ~20 more than Q1 2025). The SomaLogic acquisition closed, contributing to revenue and profitability as planned, and non-GAAP gross margin expanded 80 bps to 68.2% while non-GAAP operating margin rose ~150 bps to 21.9%. Management raised full-year guidance, reflecting the quarter’s outperformance: revenue now guided to $4.52B–$4.62B; operating margins to 23.4%–23.6%; non-GAAP diluted EPS to $5.15–$5.30. Management emphasized ongoing strength in clinical markets, continued NovaSeq X-driven consumables growth, and a disciplined cost structure amid inflationary pressures. The quarter underscored Illumina’s strategy to enhance NovaSeq X value through platform innovations, expand clinical workflows, and advance end-to-end solutions (TruPath, spatial transcriptomics, BioInsight), positioning the company for high-single-digit revenue growth and margin expansion toward 2027 targets. Risk factors include ongoing R&D/capex investments to scale NovaSeq X, macro uncertainty in research funding, and competitive pricing pressures as the industry evolves.